Page last updated: 2024-10-26

dichlorphenamide and Hyperpotassemia

dichlorphenamide has been researched along with Hyperpotassemia in 2 studies

Dichlorphenamide: A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.
diclofenamide : A sulfonamide that is benzene-1,3-disulfonamide in which the hydrogens at positions 4 and 5 are substituted by chlorine. An oral carbonic anhydrase inhibitor, it partially suppresses the secretion (inflow) of aqueous humor in the eye and so reduces intraocular pressure. It is used for the treatment of glaucoma.

Research Excerpts

ExcerptRelevanceReference
"Oral dichlorphenamide (Keveyis™) is a carbonic anhydrase inhibitor that is approved in the USA for the treatment of primary hyperkalaemic and hypokalaemic periodic paralyses and related variants."2.53Dichlorphenamide: A Review in Primary Periodic Paralyses. ( Greig, SL, 2016)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Greig, SL1
Wakabayashi, Y1

Reviews

1 review available for dichlorphenamide and Hyperpotassemia

ArticleYear
Dichlorphenamide: A Review in Primary Periodic Paralyses.
    Drugs, 2016, Volume: 76, Issue:4

    Topics: Carbonic Anhydrase Inhibitors; Clinical Trials, Phase III as Topic; Cross-Over Studies; Dichlorphena

2016

Other Studies

1 other study available for dichlorphenamide and Hyperpotassemia

ArticleYear
Hyperkalaemia induced by carbonic anhydrase inhibitor.
    The British journal of ophthalmology, 1991, Volume: 75, Issue:3

    Topics: Acidosis; Acute Kidney Injury; Aged; Aged, 80 and over; Aldosterone; Dichlorphenamide; Glaucoma; Hum

1991